Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | PPARD | Q03181 | 1/20 | 0.59 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.59 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5920648 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL17786 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL7990074 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL525378 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL524846 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL338215 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL7309478 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL123324 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL6242099 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL6238780 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105196-A1 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS | AVICENA GROUP, INC. | 2009-04-23 | — | — | US | disclosed |
| WO-2009002913-A1 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS | AVICENA GROUP, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105196-A1 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS | CKMT1A; CKMT1B, CRAT, LRAT | GPR84 313/4885FFAR1 1694/4885MAPT 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.